Sponsor or institution
Clinical trials and research at Fate Therapeutics
As of November 12, 2026, Find a Trial lists 5 clinical trials run by Fate Therapeutics that are recruiting, at sites in 4 countries (most in United States (5), France (1), Sweden (1)). By phase: Phase 1 (3), Phase 2 (1), Phase 1/2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 4Countries
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| FT839 therapy for autoimmune diseases | Phase 1/2 | Fullerton, California | Recruiting | Sep 2, 2026 |
| FT819 in Lupus Nephritis: a targeted cell therapy trial for moderate-to-severe LN | Phase 2 | Beverly Hills, California and 11 other locations | Recruiting | May 6, 2026 |
| FT836 alone or with chemotherapy and antibody drugs for advanced solid tumors. | Phase 1 | La Jolla, California and 4 other locations | Recruiting | Oct 14, 2025 |
| Evaluating FT819 for autoimmune diseases | Phase 1 | Beverly Hills, California and 20 other locations | Recruiting | Mar 13, 2024 |
| Off-the-shelf CAR-T therapy for advanced solid tumors | Phase 1 | Gilbert, Arizona and 13 other locations | Recruiting | Feb 5, 2024 |
All recruiting trials (5)
-
FT839 therapy for autoimmune diseases
This trial tests FT839, given alone or with rituximab, to see if it is safe and can help people with certain autoimmune diseases who have not responded to other treatments.
-
FT819 in Lupus Nephritis: a targeted cell therapy trial for moderate-to-severe LN
This trial tests whether FT819, a donor-derived CAR T cell therapy, can help people with difficult-to-treat lupus nephritis who have not responded to other medicines.
-
FT836 alone or with chemotherapy and antibody drugs for advanced solid tumors.
This trial will test if FT836, given alone or with paclitaxel and/or the antibodies trastuzumab or cetuximab, is safe and tolerable for people with advanced solid tumors who have already received prior treatment.
-
Evaluating FT819 for autoimmune diseases
This study is testing a new treatment called FT819 to see if it can safely help people with moderate to severe autoimmune diseases feel better.
-
Off-the-shelf CAR-T therapy for advanced solid tumors
This study is testing a new off-the-shelf CAR-T therapy called FT825 to see if it can help people with advanced solid tumors, especially those with HER2-positive cancer.
Quick answers
How many clinical trials run by Fate Therapeutics are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 4 countries. The most sites are in United States (5 trials), France (1 trial), Sweden (1 trial), United Kingdom (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 3, Phase 2: 1, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.